8-K: Coherus BioSciences Reports Strong Q1 2024 Results Driven by UDENYCA and LOQTORZI Launch

Coherus BioSciences announced positive first quarter 2024 financial results, highlighted by a significant increase in revenue and the successful launch of LOQTORZI.

Summary

• Coherus BioSciences reported a net revenue of $77.1 million for the first quarter of 2024, a substantial increase from $32.4 million in the same period last year.
• UDENYCA net product sales reached $42.7 million, showing an 18% increase compared to the previous quarter and a 63% increase year-over-year.
• The company launched UDENYCA ONBODY in February 2024, experiencing strong customer demand and payer coverage.
• LOQTORZI, launched on January 2, 2024, generated $2.0 million in net sales, aligning with early launch expectations.
• Coherus achieved a net income of $102.9 million, or $0.83 per share, compared to a net loss of $75.7 million, or $(0.96) per share, in the first quarter of 2023.
• The company divested its ophthalmology franchise for $187.8 million in cash proceeds, resulting in a net gain of $153.6 million.
• Cash, cash equivalents, and investments totaled $259.8 million as of March 31, 2024, up from $117.7 million at the end of 2023.
• Coherus projects combined R&D and SG&A expenses for 2024 to be between $250 and $265 million.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, successful product launches, and a significant improvement in profitability. The strategic divestiture and strengthened cash position further contribute to a positive sentiment.

Positives

• The company experienced substantial revenue growth in Q1 2024 compared to the same period last year.
• UDENYCA sales and market share showed significant growth, indicating strong market acceptance.
• The launch of UDENYCA ONBODY has been successful with high customer demand and payer coverage.
• LOQTORZI's launch is progressing well, with sales tracking to early launch expectations and strong payer coverage.
• The company achieved a significant net income in Q1 2024, a turnaround from the net loss in Q1 2023.
• The divestiture of the ophthalmology franchise generated a substantial gain and strengthened the company's cash position.
• The company has secured a new debt and royalty financing, replacing a $75 million term loan and extending debt maturity to May 2029.

Negatives

• Cost of goods sold increased due to higher royalty costs and product costs from new product launches.
• Selling, general, and administrative expenses increased due to a write-off of an outlicense intangible asset and higher third-party processing fees.
• Research and development expenses decreased, but this was partially offset by increased costs related to moving LOQTORZI production from China to the United States.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to clinical drug development, regulatory approvals, and competition.
• The company's 2024 R&D and SG&A expense guidance is subject to risks and uncertainties.
• The company's future operating results may not be indicative of past performance.

Future Outlook

Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million, excluding certain non-recurring items. The company is focused on becoming a sustainable and growing oncology company.

Management Comments

• Denny Lanfear, Coherus Chairman and Chief Executive Officer, stated that the company's first-quarter performance reflects its commitment to driving top-line revenues, controlling operating expenses, advancing the pipeline, and improving capital structure.
• He also noted that the progress reported aligns with the company's mission to become a sustainable and growing oncology company.

Industry Context

This announcement reflects a positive trend for Coherus in the competitive biosimilars and oncology market. The successful launch of LOQTORZI and the growth of UDENYCA position the company well against competitors. The divestiture of the ophthalmology franchise allows Coherus to focus on its core oncology business.

Comparison to Industry Standards

• Coherus's 63% year-over-year growth in UDENYCA sales is strong compared to the biosimilar market, where growth rates can vary significantly depending on product and market dynamics. For example, Amgen, the originator of Neulasta, has seen declining sales of Neulasta due to biosimilar competition.
• The 25% market share for UDENYCA is a significant achievement, indicating successful market penetration against competitors like Mylan's Fulphila and Sandoz's Ziextenzo.
• The launch of LOQTORZI and its early sales of $2.0 million are promising, especially given the challenges of launching a novel oncology drug. This compares favorably to other recent oncology drug launches, where initial sales can be slow to build.
• The net income of $102.9 million is a substantial improvement compared to the net loss in the same quarter last year, indicating effective cost management and revenue growth. This is a positive sign compared to other biotech companies that may still be operating at a loss.
• The divestiture of the ophthalmology franchise for $187.8 million is a strategic move that aligns with Coherus's focus on oncology. This is similar to other biotech companies that have divested non-core assets to streamline operations and focus on key therapeutic areas.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and strategic focus on oncology.
• Employees may experience changes due to the restructuring and divestiture, but the company's growth in oncology may create new opportunities.
• Customers will have access to new and innovative oncology treatments.
• Suppliers may see increased demand for products related to the company's oncology pipeline.
• Creditors will benefit from the company's improved financial stability and reduced debt.

Next Steps

• Coherus will continue to advance its immuno-oncology pipeline.
• The company expects to achieve formulary position with all NCCN institutions for LOQTORZI by the end of Q2 2024.
• Clinical data from the Phase 1 study of CHS-114 will be presented at the 2024 ASCO Annual Meeting in June.
• The company anticipates an FDA response on its IND filing for CHS-1000 in the second quarter of 2024.

Key Dates

Keywords

Coherus BioSciences, UDENYCA, LOQTORZI, Biosimilars, Oncology, Immunotherapy, Financial Results, Net Revenue, Market Share, Product Launch, Ophthalmology Divestiture